Roxadustat Does Not Affect Platelet Production, Activation, and Thrombosis Formation

Roxadustat is a new medication for the treatment of renal anemia. EPO (erythropoietin)—the current treatment standard—has been reported to enhance platelet activation and production. However, to date, the effect of roxadustat on platelets is unclear. To address this deficiency, herein, we have evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jiaxin, Xu, Yanyan, Xie, Jingyuan, Liu, Junling, Zhang, Ruiyan, Yan, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Basic Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454499/
https://www.ncbi.nlm.nih.gov/pubmed/34348487
http://dx.doi.org/10.1161/ATVBAHA.121.316495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454499/
https://www.ncbi.nlm.nih.gov/pubmed/34348487
http://dx.doi.org/10.1161/ATVBAHA.121.316495

Ejemplares similares